Sugi Predict

Sugi Predict / Targets / PSMC3

PSMC3

26S proteasome regulatory subunit 6A · P17980 · PSMC3 on Sugi Atlas →

7,823 patent compounds predicted against PSMC3, 6,172 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20
SCHEMBL609081 SCHEMBL609081 0.52 11/20
SCHEMBL606926 SCHEMBL606926 0.52 11/20

Clinical trials — most relevant to PSMC3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis PHASE2/PHASE3UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Bortezomib in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) PHASE2COMPLETED
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMC3 binder may also engage these)

ProteinNameSimilarity
O88685 — 1.000 O88685 →
Q63569 — 0.999 Q63569 →
O42586 — 0.999 O42586 →
O42587 — 0.998 O42587 →
Q63347 — 0.998 Q63347 →
Q54PN7 — 0.998 Q54PN7 →
P46471 — 0.998 P46471 →
O04019 — 0.997 O04019 →
P54776 — 0.997 P54776 →
O42931 — 0.996 O42931 →
Q9SEI2 — 0.996 Q9SEI2 →
P46465 — 0.996 P46465 →
Q4R4R0 — 0.996 Q4R4R0 →
PSMC2 26S proteasome regulatory subunit 7 0.996 landscape →
P54778 — 0.996 P54778 →
Q01939 — 0.996 Q01939 →
O76371 — 0.995 O76371 →
Q8SRH0 — 0.995 Q8SRH0 →
O23894 — 0.995 O23894 →
PSMC4 26S proteasome regulatory subunit 6B 0.995 landscape →
Q63570 — 0.995 Q63570 →
Q5R8D7 — 0.995 Q5R8D7 →
Q3T030 — 0.994 Q3T030 →
Q8SR13 — 0.994 Q8SR13 →
Q2KIW6 — 0.994 Q2KIW6 →
Q9SEI4 — 0.994 Q9SEI4 →
Q5E9F9 — 0.994 Q5E9F9 →
P33297 — 0.994 P33297 →
P46472 — 0.993 P46472 →
Q18787 — 0.993 Q18787 →